AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 97 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $134,000 | +106.2% | 3,876 | 0.0% | 0.01% | +100.0% |
| Q2 2020 | $65,000 | +16.1% | 3,876 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $56,000 | -56.9% | 3,876 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $130,000 | +71.1% | 3,876 | +7.4% | 0.01% | +100.0% |
| Q3 2019 | $76,000 | +1.3% | 3,609 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $75,000 | -7.4% | 3,609 | 0.0% | 0.00% | -25.0% |
| Q1 2019 | $81,000 | -5.8% | 3,609 | 0.0% | 0.00% | -20.0% |
| Q4 2018 | $86,000 | -12.2% | 3,609 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $98,000 | +1.0% | 3,609 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $97,000 | -1.0% | 3,609 | +16.8% | 0.01% | 0.0% |
| Q1 2018 | $98,000 | -16.2% | 3,089 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $117,000 | +77.3% | 3,089 | 0.0% | 0.01% | +66.7% |
| Q3 2017 | $66,000 | +3.1% | 3,089 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $64,000 | +42.2% | 3,089 | +50.8% | 0.00% | +50.0% |
| Q1 2017 | $45,000 | – | 2,048 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,295,712 | $47,524,000 | 3.98% |
| Samsara BioCapital, LLC | 232,571 | $3,354,000 | 1.93% |
| Eventide Asset Management | 3,851,000 | $55,531,000 | 1.80% |
| Burrage Capital Management LLC | 112,546 | $1,609,000 | 1.58% |
| Avidity Partners Management LP | 408,000 | $5,883,000 | 0.81% |
| RICE HALL JAMES & ASSOCIATES, LLC | 982,484 | $14,167,000 | 0.79% |
| Bullseye Asset Management LLC | 43,374 | $626,000 | 0.75% |
| Nantahala Capital Management | 1,005,302 | $14,496,000 | 0.54% |
| ARMISTICE CAPITAL, LLC | 600,000 | $8,652,000 | 0.54% |
| Values First Advisors, Inc. | 27,042 | $389,947 | 0.47% |